Background
Methods
Study population
Receptor status and mutation analysis
Statistical analysis
Results
Total n = 802 | GC-HBOC n = 649 | GBG n = 153 | |
---|---|---|---|
BRCA mutation status, no (%) | |||
negative | 675 (84.2) | 537 (82.7) | 138 (90.2) |
BRCA1 | 118 (14.7) | 107 (16.5) | 11 (7.2) |
BRCA2 | 9 (1.1) | 5 (0.8) | 4 (2.6) |
Age at diagnosis, years (median, range) | 40.1 (19.5–76.2) | 38.0 (19.5–76.2) | 48.0 (21.0–74.0) |
negative | 42.0 (19.5–76.2) | 38.7 (19.5–76.2) | 48.5 (26.0–74.0) |
BRCA1 | 34.1 (21.0–63.5) | 33.5 (25.0–63.5) | 41.0 (21.0–61.0) |
BRCA2 | 47.2 (34.3–63.1) | 47.1 (34.3–63.1) | 54.0 (39.0–63.0) |
n
|
BRCA1
|
BRCA2
|
BRCA1/2
| ||||
---|---|---|---|---|---|---|---|
n
| % (95%CI) |
n
| % (95%CI) |
n
| % (95%CI) | ||
Age group (years) | |||||||
20–29 | 85 | 28 | 32.9 (23.9–43.5) | 0 | 0.0 (0.0–4.3) | 28 | 32.9 (23.9–43.5) |
30–39 | 309 | 60 | 19.4 (15.4–24.2) | 3 | 1.0 (0.3–2.8) | 63 | 20.4 (16.3–25.2) |
40–49 | 216 | 22 | 10.2 (6.8–14.9) | 3 | 1.4 (0.5–4.0) | 25 | 11.6 (8.0–16.5) |
50–59 | 122 | 6 | 4.9 (2.3–10.3) | 1 | 0.8 (0.1–4.5) | 7 | 5.7 (2.8–11.4) |
60–69 | 58 | 2 | 3.4 (1.0–11.7) | 2 | 3.4 (1.0–11.7) | 4 | 6.9 (2.7–16.4) |
70–79 | 12 | 0 | 0.0 (0.0–24.2) | 0 | 0.0 (0.0–24.2) | 0 | 0.0 (0.0–24.2) |
TOTAL | 802 | 118 | 14.7 (12.4–17.3) | 9 | 1.1 (0.6–2.1) | 127 | 15.8 (13.5–18.5) |
Age group | Number of newly diagnosed BC cases in 2012 a | % TNBC among all BC cases b | % of TNBC w/o FH c | Number of TNBC cases w/o FH | % BRCA1/2 mutation carriers among TNBC cases w/o FH d | Number of BRCA1/2 mutation carriers among TNBC cases without FH |
---|---|---|---|---|---|---|
< 40 | 2462 | 19.8 | 62.2 | 302 | 26.3 | 79 |
40–49 | 9757 | 10.5 | 56.8 | 580 | 12.1 | 70 |
50–59 | 15,059 | 9.0 | 65.8 | 891 | 6.9 | 61 |
60–69 | 16,497 | 7.0 | 71.9 | 835 | 3.8 | 32 |
70–79 | 15,420 | 6.9 | 71.9 | 768 | 2.1 | 16 |